Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ: RCKT · Real-Time Price · USD
17.45
+0.20 (1.16%)
At close: Nov 8, 2024, 4:00 PM
17.67
+0.22 (1.26%)
After-hours: Nov 8, 2024, 4:31 PM EST
1.16%
Market Cap 1.59B
Revenue (ttm) n/a
Net Income (ttm) -258.08M
Shares Out 91.01M
EPS (ttm) -2.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 873,093
Open 17.29
Previous Close 17.25
Day's Range 16.65 - 17.66
52-Week Range 15.98 - 32.53
Beta 1.09
Analysts Strong Buy
Price Target 53.22 (+204.99%)
Earnings Date Nov 7, 2024

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell auto... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 268
Stock Exchange NASDAQ
Ticker Symbol RCKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RCKT stock is "Strong Buy." The 12-month stock price forecast is $53.22, which is an increase of 204.99% from the latest price.

Price Target
$53.22
(204.99% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

1 day ago - Business Wire

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

1 day ago - Business Wire

Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves

Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accel...

7 weeks ago - Seeking Alpha

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

7 weeks ago - Business Wire

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

2 months ago - Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

2 months ago - Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

3 months ago - Business Wire

3 Biotech Names With Potential Catalysts By Year End

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should con...

Other symbols: CADLVRDN
3 months ago - Seeking Alpha

FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy t...

4 months ago - Investopedia

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

4 months ago - Business Wire

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

5 months ago - Business Wire

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

6 months ago - Business Wire

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

6 months ago - Business Wire

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected ...

7 months ago - Seeking Alpha

Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch

EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia. A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falco...

7 months ago - Seeking Alpha

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

7 months ago - Business Wire

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

8 months ago - Business Wire

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Rocket Pharmaceuticals, Inc. stock surged 76% post a "Buy" recommendation, fueled by positive Phase 2 trial news for RP-A501 in Danon disease. RP-A501, targeting a rare disease without current treatme...

9 months ago - Seeking Alpha

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

9 months ago - Business Wire

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

9 months ago - Business Wire

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

11 months ago - Business Wire

Best Small-Cap Stocks to Buy for 2024 and Beyond

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

11 months ago - Kiplinger

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ...

11 months ago - Business Wire

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ...

1 year ago - Business Wire

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ...

1 year ago - Business Wire